


## PHARMACEUTICAL 2022

## Petros Pharmaceuticals Inc. Rank 140 of 475







## PHARMACEUTICAL 2022

## Petros Pharmaceuticals Inc. Rank 140 of 475



The relative strengths and weaknesses of Petros Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Petros Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 146% points. The greatest weakness of Petros Pharmaceuticals Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 5.3%, being 282% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	30,543
Cost of Goods Sold	1,600
Intangible Assets	25,293
Liabilities, Current	30,980
Liabilities, Non-Current	405
Other Assets	11,505
Other Compr. Net Income	0
Other Expenses	7,247
Other Liabilities	460
Other Net Income	9,430
Property and Equipment	49
Research and Development	1,788
Revenues	7,811
Selling, General and Administrative Expense	15,593

Output Variable	Value in 1000 USD
Assets	67,390
Liabilities	31,845
Expenses	26,228
Stockholders Equity	35,545
Net Income	-8,987
Comprehensive Net Income	-8,987
Economic Capital Ratio	5.3%